The purchase will bolster its cancer fighting pipeline. Drug manufacturer Bristol-Myers Squibb disclosed it would be acquiring privately held IFM Therapeutics for $300 million. The acquisition, backed by Novartis, will boost its cancer portfolio, since it will be able to access IFM’s preclinical cancer programs. Incidentally, IFM investors are also eligible to additional contingent payments…